Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
Despite Astrazeneca stacking the odds in its favour Imfinzi’s Danube trial, in first-line bladder cancer, reads out negatively.
A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.
Astrazeneca reckons a bispecific approach can unlock the potential of CTLA-4 inhibition, and is to start a large phase II programme this year.
With eight phase III trials in three different indications, Lilly is investing heavily in mirikizumab. The first pivotal data, in psoriasis, will emerge soon.
Adjuvant and neoadjuvant settings are an important target for Roche’s Tecentriq, but how likely is the drug to become broadly applicable?
A fresh blow to the beta-amyloid hypothesis has not rattled Biogen's supporters, but Lilly shareholders were apparently hoping for more.
The academic Dian-Tu study looks at anti-amyloid beta antibodies from Lilly and Roche; despite gantenerumab, hopes are being dialled back.
Tackling the CD47 pathway has seen off several industry players, but Forty Seven continues proudly flying the flag.